AMGN Gets FDA Nod, Uncertainty Ends For CEMP, Clock Is Ticking For ANTH

Anthera Pharmaceuticals Inc. (ANTH) is all set to report top line data from a phase III study of Blisibimod for the treatment of systemic lupus erythematosus, dubbed CHABLIS-SC1, before November 11, 2016.

from RTT - Biotech http://ift.tt/2ettDVz
via IFTTT